Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa.
Nat Rev Microbiol
; 18(12): 690-704, 2020 12.
Article
in English
| MEDLINE | ID: covidwho-759598
ABSTRACT
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a global pandemic, prompting unprecedented efforts to contain the virus. Many developed countries have implemented widespread testing and have rapidly mobilized research programmes to develop vaccines and therapeutics. However, these approaches may be impractical in Africa, where the infrastructure for testing is poorly developed and owing to the limited manufacturing capacity to produce pharmaceuticals. Furthermore, a large burden of HIV-1 and tuberculosis in Africa could exacerbate the severity of infection and may affect vaccine immunogenicity. This Review discusses global efforts to develop diagnostics, therapeutics and vaccines, with these considerations in mind. We also highlight vaccine and diagnostic production platforms that are being developed in Africa and that could be translated into clinical development through appropriate partnerships for manufacture.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Country/Region as subject:
Africa
Language:
English
Journal:
Nat Rev Microbiol
Journal subject:
Microbiology
Year:
2020
Document Type:
Article
Affiliation country:
S41579-020-00441-3
Similar
MEDLINE
...
LILACS
LIS